All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Lymphoma Hub was pleased to speak to Constantine Tam, Peter MacCallum Cancer Centre, Melbourne, AU. In this video, he discusses the phase III ASPEN trial, where treatment with the two Bruton's tyrosine kinase (BTK) inhibitors, zanubrutinib and ibrutinib, were compared in patients with Waldenström macroglobulinemia.
Constantine Tam, explains the mechanism of action of the two drugs, the patient response rates and safety results of the two treatment arms. He also explains that although the trial did not meet its primary endpoint (very good partial response), zanubrutinib showed greater tolerability and safety compared to ibrutinib.
ASPEN trial: zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Novel combinations for R/R MCL: Key updates from ASH 2022
The article predominantly focuses on results presented at ASH 2022 from interventional studies of novel combination therapies in relapsed/refractory (R/R) mantle cell lymphoma (MCL).
Educational theme: Advances in treating Waldenström's macroglobulinemia
Over the next month, the Lymphoma Hub will be focusing on a new educational theme: Advances in treating Waldenström's macroglobulinemia. This article introduces the topic and...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox